These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3564003)

  • 1. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of o,p'-DDD on cortisol metabolism in Cushing's syndrome of various etiology.
    Koide Y; Inoue S; Murayama H; Kawai K; Yamashita K
    Endocrinol Jpn; 1985 Oct; 32(5):615-24. PubMed ID: 3004927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease].
    Ojima M; Hashimoto S; Itoh N; Kusano Y; Satoh K; Egawa M; Gomibuchi T; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1988 Jun; 64(6):451-62. PubMed ID: 3145221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
    Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
    Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carcinoma of the adrenal cortex].
    Hamborg B; Frey H; Bøhmer T; Norman N
    Tidsskr Nor Laegeforen; 1990 Mar; 110(8):956-9. PubMed ID: 2321225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results of the use of mitotane for adrenocortical carcinoma.
    Kasperlik-Zaluska AA
    Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Heilmann P; Wagner P; Nawroth PP; Ziegler R
    Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.
    Moolenaar AJ; van Slooten H; van Seters AP; Smeenk D
    Cancer Chemother Pharmacol; 1981; 7(1):51-4. PubMed ID: 7340988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
    Lim MC; Tan YO; Chong PY; Cheah JS
    Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
    Schwarte S; Brabant EG; Bastian L; Bruns F
    Anticancer Res; 2007; 27(4A):1917-20. PubMed ID: 17649795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide.
    Scott RD
    Postgrad Med J; 1975 Jan; 51(591):35-7. PubMed ID: 1161676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
    Lindhe O; Skogseid B
    Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient.
    Dickerman Z; Kaufman H; Laron Z
    Isr J Med Sci; 1979 May; 15(5):455-9. PubMed ID: 447515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of Cushing's disease and multiple myeloma.
    Kinugawa T; Shigemasa C; Adachi T; Okamura Y; Yoshida A; Mashiba H
    Jpn J Med; 1989; 28(5):616-20. PubMed ID: 2585890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.